European urology oncology最新文献

{"title":"Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.","authors":"Nobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, Ernesto Korbenfeld, Rustem Gafanov, Loïc Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries M Bergman, Pawel Zalewski, Maria De Santis, Andrew J Armstrong, Winald Gerritsen, Russell K Pachynski, Todd L Saretsky, Sameer R Ghate, Fan Wang, Charles Schloss, Karim Fizazi","doi":"10.1016/j.euo.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.euo.2025.02.015","url":null,"abstract":"<p><strong>Background and objective: </strong>In the phase 3 KEYNOTE-921 study, the combination of pembrolizumab with docetaxel did not improve efficacy outcomes significantly in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) after next-generation hormonal agents (NHAs). This analysis of KEYNOTE-921 assessed patient-reported outcomes (PROs) associated with pembrolizumab plus chemotherapy versus chemotherapy alone.</p><p><strong>Methods: </strong>Eligible patients were assigned randomly in a 1:1 ratio to receive pembrolizumab or placebo, both with docetaxel and prednisone. The time to pain progression measured by the Brief Pain Inventory-Short Form was a secondary end point. Health-related quality of life (HRQoL) scores, including disease-related symptoms, assessed by the Functional Assessment of Cancer Therapy-Prostate and EuroQol five-dimension five-level were prespecified exploratory end points.</p><p><strong>Key findings and limitations: </strong>The PRO analysis set comprised 1028 patients; the median follow-up was 22.7 mo from baseline until database cutoff (June 20, 2022). The median time to pain progression was 21.1 mo (95% confidence interval [CI] 13.7 to not reached [NR]) and NR (95% CI 13.8-NR) in the pembrolizumab and placebo arms, respectively (hazard ratio 1.05; 95% CI 0.77-1.43). Changes from baseline in PRO end points were similar between treatment arms and remained generally stable throughout the study. Limitations include a lack of formal hypothesis testing to detect between-arm differences in PROs.</p><p><strong>Conclusions and clinical implications: </strong>No meaningful differences in PROs were observed in patients with mCRPC treated with pembrolizumab plus chemotherapy versus chemotherapy alone. These findings indicate that adding an immune checkpoint inhibitor to chemotherapy does not positively or negatively impact HRQol in patients with mCRPC previously treated with NHAs.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer.","authors":"Nicole Handa, Eric V Li, Jamie Michael, James A Proudfoot, Adam B Weiner, Ridwan Alam, Mohammed Alshalalfa, Yangyang Hao, Alex Hakansson, Xin Zhao, Yang Liu, Elai Davicioni, Phillip G Febbo, Hiten D Patel, David J VanderWeele, Edward M Schaeffer, Ashley E Ross","doi":"10.1016/j.euo.2025.04.022","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.022","url":null,"abstract":"<p><strong>Background and objective: </strong>Systemic therapies that have shown a benefit in advanced prostate cancer are being evaluated in earlier disease stages. We sought to determine the prevalence of transcriptomic changes in signatures related to treatment susceptibilities in patients with nonmetastatic prostate cancer.</p><p><strong>Methods: </strong>Patients with nonmetastatic prostate cancer with Decipher genomic classifier and whole-transcriptome profiling data for biopsy specimens from October 2016 to February 2024 were included (n = 140 548). Predefined treatment-related signatures of androgen receptor activity (AR-A), PTEN loss, homologous recombination deficiency (HRD), RB loss, immune activity, and prostate-specific membrane antigen (PSMA; FOLH1) expression, along with Decipher scores and prostate cancer subtypes, were assessed.</p><p><strong>Key findings and limitations: </strong>The prevalence of low AR-A scores and the basal subtype, which are associated with lower responsiveness to androgen deprivation therapy (ADT), increased with American Joint Committee on Cancer (AJCC) stage and Decipher genomic risk. The prevalence of cancers with a potential response to PI3K inhibitors, according to PTEN loss, and a response to PARP inhibitors, according to HRD status, also increased with AJCC stage and Decipher genomic risk score (all p < 0.001). The prevalence of high PSMA expression was greater in AJCC grade IIC-IIIC disease, so these patients would be potential candidates for PSMA radioligand therapies. More than 60% of patients with AJCC grade IIC-IIIC disease and very high Decipher scores (>0.85) are potential candidates for targeted therapies.</p><p><strong>Conclusions and clinical implications: </strong>Treatment-related signature scores vary by AJCC stage and Decipher score and may be useful in guiding trials and selecting targeted therapies for nonmetastatic prostate cancer. Higher-stage prostate cancers appear to be more basal and androgen-independent, and thus may be more susceptible to intensified ADT + androgen receptor pathway inhibitors or therapies targeting PARP or PSMA.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis.","authors":"Olivier Cussenot, Yoann Taille, Jean-Jacques Portal, Géraldine Cancel-Tassin, Morgan Rouprêt, Alexandre de la Taille, Guillaume Ploussard, Romain Mathieu, Eric Vicaut","doi":"10.1016/j.euo.2025.04.024","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.024","url":null,"abstract":"<p><p>Several large analyses have revealed contradictory results regarding the association between prostate cancer (PC) survival and the use of statins prescribed for prevention of dyslipidaemia or atherosclerosis complications, or of metformin prescribed for type 2 diabetes (T2D). Using data collected between 2006 and 2018 in French national health databases for 521 052 men with PC and 1 827 345 men without PC, we evaluated current evidence regarding overall survival for men with PC according to statin and/or metformin use. The highest mortality was observed in PC patients exposed to both statins and metformin (hazard ratio [HR] 2.29, 95% confidence interval [CI] 2.25-2.33). However, for patients whose first PC treatment was androgen deprivation therapy, a protective effect was observed for statin alone exposure (HR 0.91, 95% CI 0.88-0.93) and combined statin and metformin exposure (HR 0.86, 95% CI 0.85-0.87), whereas men with metformin exposure alone had higher mortality (HR 1.07, 95% CI 1.03-1.11) in comparison to non-users. This protective effect of statins was not observed for PC patients treated with radical prostatectomy. The result was confirmed using causal analysis in a Bayesian network, followed by semantic elicitation using generative artificial intelligence that compiles web-based human knowledge and dedicated literature.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer.","authors":"Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Florian Roghmann, Nicolas von Landenberg, Joachim Noldus, Daniela Jahn, Karoline Kernig, Oliver W Hakenberg, Peter J Goebell, Jörg Hennenlotter, Eva Erne, Arnulf Stenzl, Maciej Rowinski, Guido Schiffhorst, Thomas Baranek, Natalya Benderska-Söder","doi":"10.1016/j.euo.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.020","url":null,"abstract":"<p><strong>Background and objective: </strong>A growing body of evidence suggests that the intensity of current follow-up in non-muscle-invasive bladder cancer (NMIBC) patients greatly exceeds clinical necessities. The UroFollow trial investigated the diagnostic accuracy of marker-based follow-up in patients with low/intermediate-risk NMIBC against the standard of care (SOC) for noninferiority (margin: <20%).</p><p><strong>Methods: </strong>Patients with Ta low- and high-grade (G1-2) NMIBC were randomized to the SOC or 6-monthly marker-based follow-up (algorithm comprising urine markers and ultrasound; marker-based surveillance regimen [MA]). After a negative 3-mo cystoscopy (white light cystoscopy [WLC]), only patients with a positive algorithm underwent WLC in the MA. End-of-study WLC was recommended at 3 yr to recurrence-free patients. Simultaneously, several innovative urine markers were examined.</p><p><strong>Key findings and limitations: </strong>In total, 214 patients were randomized to the SOC (n = 109) and MA (n = 105). The median follow-up was 2.4 yr; 30 and 29 cases of tumor recurrence were diagnosed in the SOC and MA arms, respectively. Sensitivity was 96.5% versus 81.5% (p = 0.1), with one and five Ta low-grade tumors being overlooked in the SOC and MA patients, respectively. No tumor progressing in stage or grade was missed. A total of 589 WLC procedures were performed in the SOC and 148 in the MA arm (p < 0.001). Among five other markers (ADX-Bladder, CellDetect, Bladder EpiCheck, UBC rapid, and Xpert bladder cancer monitor [BC-M]), Bladder EpiCheck and the Xpert BC-M showed similar performance to the algorithm.</p><p><strong>Conclusions and clinical implications: </strong>UroFollow is the first urine marker-based randomized trial in low/intermediate-risk NMIBC patients. We conclude that 6-monthly marker-based follow-up after negative 3-mo WLC is safe in this cohort. Results of contemporary urine markers suggest that their potential for use in marker-based surveillance, however, requires prospective confirmation.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.","authors":"Noelia Sanmamed, Ian Dayes, Charles Catton, Amy Liu, Stephane Supiot, Himu Lukka, Glenn Bauman, Zijin Liu, Jean-Paul Bahary, Shahida Ahmed, Patrick Cheung, Matthew Parliament, Michael Sia, Theodorus Tsakiridis, Shankar Siva, Tom Corbett, Colin Tang, Tim Craig, Jarad Martin, Peter Chung","doi":"10.1016/j.euo.2025.03.017","DOIUrl":"https://doi.org/10.1016/j.euo.2025.03.017","url":null,"abstract":"<p><strong>Background and objective: </strong>The PROFIT trial was designed to compare moderately hypofractionated (HF) radiotherapy versus conventional fractionation (CF) for patients with intermediate-risk prostate cancer (IR-PC). Similar efficacy and toxicity outcomes were previously reported. The aim of the current analysis was to evaluate differences in long-term patient-reported outcomes (PROs) between the HF and CF arms in PROFIT.</p><p><strong>Methods: </strong>For the PROFIT phase 3 randomized clinical trial, patients with IR-PC (n = 1206) were enrolled from 14 sites in Canada, 12 in Australia, and one in France and randomized to receive 78 Gy in 39 fractions over 8 wk (CF) or 60 Gy in 20 fractions over 4 wk (HF). PROs were evaluated at baseline and 24 and 48 mo using the Expanded Prostate Cancer Index Composite, American Urological Association Symptom Score (AUASS), and the 12-item Short Form Health Survey (SF-12) comprising a physical component summary (PCS) and a mental component summary (MCS). A minimally important difference (MID) was defined as a deterioration in domain- or subdomain-specific health-related quality of life (HRQoL) score by ≥0.5 times the standard deviation at each time point in comparison to baseline. Statistical significance was set at p < 0.01.</p><p><strong>Key findings and limitations: </strong>AUASS results were similar and stable over time in both arms (median 5 points, interquartile range 2-9; p > 0.2). There were no significant differences in scores for urinary, bowel, sexual, and hormonal domains or subdomains between the arms at any time point (p > 0.02). The greatest decline over time occurred in sexual domain, with a decrease of ≥10 points from baseline to 24 mo in both arms. SF-12 mean scores for both PSC and MSC were similar in the two arms and remained stable at all time points. The only significant differences in the proportion of patients reporting MIDs were for the bowel subdomains at 48 mo, with significant MID reductions favoring HF for both the bowel summary score (53% vs 44%; p = 0.01) and bowel function score (51% vs 39%; p = 0.001). Overall treatment satisfaction was high in both arms: ≥88% of patients were either satisfied or extremely satisfied with their treatment.</p><p><strong>Conclusions and clinical implications: </strong>PRO results from the PROFIT trial suggest no significant differences in urinary, bowel, sexual, hormonal, and general HRQoL between CF and HF radiotherapy schedules. This study provides level 1 evidence supporting the use of moderate HF radiotherapy as standard treatment in patients with IR-PC. This trial is registered on ClinicalTrials.gov as NCT00304759.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Giacomo Gallo, Alessio Guidotti, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Rosemarijn H. Ettema, Jan-Jaap J. Mellema, Dennie Meijer, et al. Early Oncological Outcomes in Patients Who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.11.003.","authors":"André N Vis, Rosemarijn H Ettema","doi":"10.1016/j.euo.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.019","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Profiling FGFR3 Expression Based on the Immune Micro-environment in Upper Tract Urothelial Carcinoma\" [Eur. Urol. Oncol. 7(6) (2024) 1338-1349].","authors":"Keisuke Shigeta, Kazuhiro Matsumoto, Sotaro Kitaoka, Minami Omura, Kota Umeda, Yuki Arita, Shuji Mikami, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Takeo Kosaka, Ryuichi Mizuno, Satoshi Hara, Mototsugu Oya","doi":"10.1016/j.euo.2025.04.023","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.023","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer.","authors":"Jianliang Liu, Laurence Harewood, Dominic Bagguley, Philip Dundee, George Mirmilstein, Declan G Murphy, Yee Chan, Daniel Moon, Paul Kearns, Prassannah Satasivam, Marlon Perera, Dixon T S Woon, Fairleigh Reeves, Dinesh K Agarwal, Justin Peters, Darren Katz, Mariolyn Raj, Renu Eapen, Shomik Sengupta, Niall Corcoran, Thilakavathi Chengodu, Andrew Ryan, Kenny Sim, Wayland Wang, James Sheldon, Nathan Lawrentschuk","doi":"10.1016/j.euo.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.euo.2025.02.010","url":null,"abstract":"<p><strong>Background and objective: </strong>There is growing evidence on the utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) for detection of clinically significant prostate cancer (csPC), but there are limited data on its use in active surveillance (AS). The CONFIRM trial aims to determine the utility of PSMA PET/CT in detecting csPC before confirmatory biopsy during AS.</p><p><strong>Methods: </strong>This is an initial analysis of a prospective, nonrandomised, crossover clinical trial (ANZCTR ID ACTRN12621001648819) that included men on AS for newly diagnosed low-grade prostate cancer (PC) with \"high-risk\" features. High risk was defined as grade group (GG) 1 disease with elevated prostate-specific antigen (PSA; >10 ng/ml, or PSA density >0.15 ng/ml/ml), high-volume GG 1, GG 1 with Prostate Imaging-Reporting and Data System 4 or 5 lesion on magnetic resonance imaging (MRI), or low-volume GG 2 PC. Patients underwent multiparametric MRI and [¹⁸F]-labelled radioligand PSMA PET/CT 3-6 mo after diagnosis, and confirmatory biopsy 6-9 mo after diagnosis.</p><p><strong>Key findings and limitations: </strong>Between November 2021 and September 2023, 60 patients (median age 62.5 yr) were enrolled. PSMA-avid lesions were identified in 44 patients (73.3%), of whom 27 (61.4%) harboured csPC (GG ≥2). Of the PSMA-avid lesions, 20 (45.5%) were MRI-occult. At a subsequent multidisciplinary meeting, active treatment was recommended for 24 patients (40%), with PSMA PET/CT findings influencing 12 (20%) of the decisions. PSMA PET/CT provided reassurance regarding the decision to continue AS by excluding PSMA-avid lesions in 14 cases (38.9%) and multifocal disease in four (11.1%). Our findings are limited by the small sample size and short follow-up.</p><p><strong>Conclusions and clinical implications: </strong>PSMA PET/CT appears to hold promise for improving risk stratification during AS by identifying csPC and MRI-occult lesions.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Prior PARP Inhibitor Exposure with Clinical Outcomes After ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.","authors":"Mona Kafka, Giulia Giannini, Isabel Heidegger","doi":"10.1016/j.euo.2025.02.017","DOIUrl":"https://doi.org/10.1016/j.euo.2025.02.017","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Active Surveillance of Grade Group 2 Prostate Cancer- Oncological Outcomes from a Contemporary European Cohort.","authors":"Isabel Heidegger, Jasmin Bektic","doi":"10.1016/j.euo.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.021","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}